For the quarter ended June 2024, Astrazeneca (AZN) reported revenue of $12.94 billion, up 13.3% over the same period last year. EPS came in at $0.99, compared to $1.08 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $12.48 billion, representing a surprise of +3.70%. The company delivered an EPS surprise of +3.13%, with the consensus EPS estimate being $0.96.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how the ...

AstraZeneca’s (AZN) second-quarter 2024 core earnings of 99 cents per American depositary share (ADS) beat the Zacks Consensus Estimate of 96 cents. Core earnings of $1.98 per share fell 8% year over year on a reported basis and 3% at constant exchange rates (CER).Total revenues of $12.94 billion rose 13% on a reported basis and 17% at CER, driven by rising product sales and continued growth in Alliance revenues from partnered medicines. Revenues also beat the Zacks Consensus Estimate of $12.48 billion.All ...

FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2024 Commission File Number: 001-11960 AstraZeneca PLC 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA England Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is sub ...

Key TakeawaysAstraZeneca's second-quarter earnings beat expectations Thursday, and the drugmaker also lifted its guidance.Like its COVID-19 vaccine manufacturing colleagues Pfizer and Johnson & Johnson, AstraZeneca's revenue from vaccines fell year-over-year.During the quarter, the company said at its annual investor day that it believes the drugs in its development pipeline can boost revenue to $80 billion annually by 2030, compared to $45 billion in 2023. AstraZeneca (AZN) posted better-than-expected resu ...

Pinetree to receive up to $45 million in upfront and near-term payments, with a total deal value of over $500 million including potential additional development and commercial milestone payments CAMBRIDGE, Mass., July 23, 2024 /PRNewswire/ -- Pinetree Therapeutics, Inc. ("Pinetree" or the "Company"), a biotechnology company pioneering next generation targeted protein degraders (TPD) to combat drug resistance in oncology and beyond, today announced it has entered into an exclusive option and global license a ...

AstraZeneca (AZN) will report its second-quarter earnings on Jul 25, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $12.57 billion and 96 cents per share, respectively. Earnings estimates for AstraZeneca have risen from $4.04 per share to $4.05 per share for 2024 and from $4.67 per share to $4.69 per share for 2025 over the past 30 days.Image Source: Zacks Investment ResearchEarnings Surprise HistoryThe healthcare bellwether’s performance has been mixed, with the compan ...

Shutter2U Investment Overview In the first of my two most recent pieces of coverage for Seeking Alpha on AstraZeneca PLC (NASDAQ:AZN), the Anglo / Swedish Pharma giant, I gave the company and its stock a “buy” recommendation in February. This was after a sell-off in response to a Q4 2023 earnings miss created a buying opportunity. Then, in late May, I gave it a “hold” recommendation, shortly after the company had revealed ambitious plans to exceed $80bn in top-line revenues by 2030. AstraZeneca stock is ...

AstraZeneca’s (AZN) stock has risen 18.4% so far this year, underperforming an increase of 23.4% for the industry, as seen in the chart below. AstraZeneca’s stock has, however, outperformed the sector as well as the S&P 500.AstraZeneca Stock Performance Image Source: Zacks Investment ResearchAstraZeneca boasts a diversified geographical footprint as well as product portfolio with several blockbuster medicines. AstraZeneca now has 12 blockbuster medicines in its portfolio with sales exceeding $1 billion, inc ...

Core Insights - Amolyt Pharma has been acquired by AstraZeneca for a total consideration of up to $1.05 billion, enhancing AstraZeneca's rare disease pipeline and expanding its bone metabolism franchise [3]. Group 1: Acquisition Details - The acquisition includes an upfront payment of $800 million at deal closing, with an additional contingent payment of $250 million based on achieving a specified regulatory milestone [3]. - The acquisition is expected to bolster the Alexion, AstraZeneca Rare Disease late-stage pipeline, particularly with the addition of eneboparatide (AZP-3601), a Phase III investigational therapeutic peptide [2]. Group 2: Product and Pipeline Expansion - Enebo paratide (AZP-3601) is designed to address hypoparathyroidism, a condition caused by a deficiency in parathyroid hormone (PTH) production, leading to significant calcium and phosphate dysregulation [2]. - Amolyt Pharma's portfolio also includes AZP-3813, a peptide growth hormone receptor antagonist aimed at treating acromegaly, indicating a focus on rare endocrine diseases [4].

AstraZeneca (AZN) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its PD-L1 inhibitor Imfinzi (durvalumab) as a treatment for certain patients with primary advanced or recurrent endometrial cancer.The CHMP recommended the approval of Imfinzi plus chemotherapy, followed by Imfinzi and Lynparza as a first-line treatment for patients with mismatch repair proficient (pMMR) advanced or recurrent endometrial cancer.The CHMP ...